Effect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetes

Simple item page
dc.contributor.buuauthorGül, Özen Öz
dc.contributor.buuauthorKıyıcı, Sinem Kücçuüksaraç
dc.contributor.buuauthorErsoy, Canan
dc.contributor.buuauthorCander, Soner
dc.contributor.buuauthorYorulmaz, Hakan
dc.contributor.buuauthorGül, Cuma Bülent
dc.contributor.buuauthorSarandöl, Emre
dc.contributor.buuauthorKırhan, Emine
dc.contributor.buuauthorSığırlı, Deniz
dc.contributor.buuauthorErtürk, Erdinç
dc.contributor.buuauthorTuncel, Ercan
dc.contributor.buuauthorİmamoğlu, Sazi
dc.contributor.buuauthorÜnal, Oğuz Kağan
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji ve Metabolizma Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Dahiliye Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0003-2467-9356tr_TR
dc.contributor.orcid0000-0002-2593-7196tr_TR
dc.contributor.researcheridAAI-1005-2021tr_TR
dc.contributor.researcheridA-7063-2018tr_TR
dc.contributor.researcheridAAJ-6536-2021tr_TR
dc.contributor.researcheridAAA-7472-2021tr_TR
dc.contributor.researcheridABE-1716-2020tr_TR
dc.contributor.researcheridAAH-8861-2021tr_TR
dc.contributor.scopusid26040787100tr_TR
dc.contributor.scopusid12753880400tr_TR
dc.contributor.scopusid6701485882tr_TR
dc.contributor.scopusid25027068600tr_TR
dc.contributor.scopusid24438635700tr_TR
dc.contributor.scopusid23988796000tr_TR
dc.contributor.scopusid55943324800tr_TR
dc.contributor.scopusid37104411100tr_TR
dc.contributor.scopusid24482063400tr_TR
dc.contributor.scopusid7005488796tr_TR
dc.contributor.scopusid7006929833tr_TR
dc.contributor.scopusid55042241400tr_TR
dc.date.accessioned2022-03-16T07:42:40Z
dc.date.available2022-03-16T07:42:40Z
dc.date.issued2011-11
dc.description.abstractAim: Sitagliptin is not associated with weight gain and has neutral effects on body weight. It is unclear whether sitagliptin treatment alters serum ghrelin levels in people with type 2 diabetes. Methods: Forty-four subjects with type 2 diabetes were randomly assigned to receive sitagliptin or medical nutrition therapy (MNT) for 12 weeks. Changes in anthropometric variables, glycemic control, insulin resistance, lipid parameters, and total ghrelin levels were evaluated at baseline and following 12 weeks of treatment. Results: Significant decreases in body weight and body mass index were observed over the entire study period in both treatment groups. Glycosylated hemoglobin and postprandial plasma glucose levels were statistically significant decreased in the groups receiving sitagliptin compared with baseline values (p = 0.021 and p = 0.021, respectively), while they were unchanged in the groups receiving MNT. There was a significant decrease in total ghrelin in the groups receiving sitagliptin (p = 0.04) compared with baseline values but not in the groups receiving MNT (p = 0.46) at the end of the 12 weeks. Conclusions: In this study of patients with type 2 diabetes, treatment with sitagliptin was associated with a significant decrease in serum ghrelin levels. These results suggest that the neutral effect of sitagliptin on weight might be associated with the suppression of fasting serum ghrelin levels.en_US
dc.identifier.citationGül, O. O. vd. (2011). "Effect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetes". Diabetes Research and Clinical Practice, 94(2), 212-216.en_US
dc.identifier.endpage216tr_TR
dc.identifier.issn0168-8227
dc.identifier.issn1872-8227
dc.identifier.issue2tr_TR
dc.identifier.pubmed21855160tr_TR
dc.identifier.scopus2-s2.0-81255160708tr_TR
dc.identifier.startpage212tr_TR
dc.identifier.urihttps://doi.org/10.1016/j.diabres.2011.07.031
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/21855160/
dc.identifier.urihttp://hdl.handle.net/11452/25067
dc.identifier.volume94tr_TR
dc.identifier.wos000297153500018tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherElsevier Irelanden_US
dc.relation.journalDiabetes Research and Clinical Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEndocrinology & metabolismen_US
dc.subjectSitagliptinen_US
dc.subjectDiabetes mellitus type 2en_US
dc.subjectGhrelinen_US
dc.subjectBody weighten_US
dc.subjectIncretin-based therapiesen_US
dc.subjectCirculating ghrelinen_US
dc.subjectInsulin therapyen_US
dc.subjectWeight-gainen_US
dc.subjectMetforminen_US
dc.subjectInhibitoren_US
dc.subjectStomachen_US
dc.subjectPeptideen_US
dc.subject.emtreeGhrelinen_US
dc.subject.emtreeGlycosylated hemoglobinen_US
dc.subject.emtreeSitagliptinen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBody massen_US
dc.subject.emtreeBody weighten_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDiabetes controlen_US
dc.subject.emtreeDiet therapyen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeGlucose blood levelen_US
dc.subject.emtreeHormone blood levelen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeInsulin resistanceen_US
dc.subject.emtreeLipid blood levelen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMonotherapyen_US
dc.subject.emtreeNon insulin dependent diabetes mellitusen_US
dc.subject.emtreeRandomized controlled trialen_US
dc.subject.emtreeTreatment responseen_US
dc.subject.meshAgeden_US
dc.subject.meshAnalysis of varianceen_US
dc.subject.meshBiological markersen_US
dc.subject.meshBlood glucoseen_US
dc.subject.meshBody mass indexen_US
dc.subject.meshBody weighten_US
dc.subject.meshChi-square distributionen_US
dc.subject.meshDiabetes mellitus, type 2en_US
dc.subject.meshDipeptidyl-peptidase IV inhibitorsen_US
dc.subject.meshDown-regulationen_US
dc.subject.meshFemaleen_US
dc.subject.meshGhrelinen_US
dc.subject.meshHemoglobin a, glycosylateden_US
dc.subject.meshHumansen_US
dc.subject.meshHypoglycemic agentsen_US
dc.subject.meshLipidsen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshPyrazinesen_US
dc.subject.meshTime factorsen_US
dc.subject.meshTreatment outcomeen_US
dc.subject.meshTriazolesen_US
dc.subject.meshTurkeyen_US
dc.subject.scopusDipeptidyl Peptidase IV Inhibitor; Non Insulin Dependent Diabetes Mellitus; Sulfonylureaen_US
dc.subject.wosEndocrinology & metabolismen_US
dc.titleEffect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetesen_US
dc.typeArticle
dc.wos.quartileQ2en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus